USANA Health Sciences (NYSE:USNA) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why

USANA Health Sciences, Inc. (NYSE:USNA) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $19.50 and traded as high as $22.32. USANA Health Sciences shares last traded at $22.0650, with a volume of 69,850 shares trading hands.

Analyst Upgrades and Downgrades

USNA has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research report on Wednesday, June 24th. Zacks Research downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. Finally, Wall Street Zen upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, June 20th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Reduce”.

USANA Health Sciences Stock Performance

The stock has a 50-day simple moving average of $19.34 and a 200 day simple moving average of $19.50. The company has a market cap of $407.32 million, a P/E ratio of 46.95, a P/E/G ratio of 0.86 and a beta of 0.73.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.17. The business had revenue of $250.22 million for the quarter, compared to analysts’ expectations of $240.99 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Sell-side analysts anticipate that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at USANA Health Sciences

In other news, insider Joshua Foukas sold 3,791 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $19.82, for a total transaction of $75,137.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John Turman Fleming sold 2,450 shares of USANA Health Sciences stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $17.93, for a total transaction of $43,928.50. Following the sale, the director owned 4,230 shares in the company, valued at approximately $75,843.90. This trade represents a 36.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 17,660 shares of company stock worth $336,579. Corporate insiders own 0.82% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its stake in shares of USANA Health Sciences by 1.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock valued at $22,522,000 after purchasing an additional 21,793 shares during the period. Vanguard Group Inc. lifted its position in shares of USANA Health Sciences by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock worth $29,452,000 after buying an additional 57,249 shares during the period. Dimensional Fund Advisors LP boosted its stake in USANA Health Sciences by 1.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock valued at $25,210,000 after buying an additional 17,318 shares in the last quarter. Nantahala Capital Management LLC acquired a new stake in USANA Health Sciences in the 4th quarter valued at $11,485,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in USANA Health Sciences by 22.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 353,946 shares of the company’s stock valued at $6,948,000 after buying an additional 65,867 shares in the last quarter. Institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.